Shukla Tulika, Nadella Ravi Kumar, Taj M J Reshma Jabeen, Ganesh Suhas, Nestadt Gerald, Purushottam Meera, Jain Sanjeev, Reddy Y C Janardhan, Viswanath Biju
Department of Psychiatry, National Institute of Mental Health and Neurosciences.
Molecular Genetics Laboratory, National Institute of Mental Health and Neurosciences.
Exp Clin Psychopharmacol. 2020 Dec;28(6):617-621. doi: 10.1037/pha0000348. Epub 2020 Jan 27.
The glutamate transporter gene SLC1A1 has been shown to have an association with obsessive-compulsive disorder (OCD), and serotonin reuptake inhibitor (SRI) treatment response. One polymorphism (rs3056) in SLC1A1 has been associated with altered brain volumes in OCD. We investigated the association of this polymorphism with OCD and its relationship with various clinical parameters, including age of onset, disease severity, insight, factor analyzed symptom dimensions of OCD, and SRI treatment response. Three hundred seventy seven OCD patients (DSM-IV) aged between 18 to 60 years were recruited from a specialty OCD clinic. To study the association with SRI treatment response, we analyzed full responders (≥35% reduction in the Yale Brown Obsessive Compulsive Scale [YBOCS] and the Clinical Global Impression-Improvement [CGI-I] score of 1 or 2) to any SRI (n = 187) and nonresponders (<25% reduction in the YBOCS and the CGI-I score >4) to adequate trials of at least two SRIs for a duration of 12 weeks (n = 91). Healthy controls (n = 333) were recruited and evaluated using the Mini-International Neuropsychiatric Interview-Plus (MINI-Plus). All subjects were from southern India, and were genotyped for the SLC1A1 polymorphism (rs3056). Genotype frequencies did not deviate significantly from the Hardy-Weinberg equilibrium. Case-control association analysis revealed that the "GG" genotype was significantly more frequent in OCD cases than the controls (p = .04). No association was found with the age of onset, symptom severity, insight, and symptom dimensions. No significant association was found between genotype/allele frequencies with treatment response. To conclude, although there was a significant association between the SLC1A1 rs3056 polymorphism and OCD, there were no significant associations with other clinical parameters or treatment response. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
谷氨酸转运体基因SLC1A1已被证明与强迫症（OCD）以及5-羟色胺再摄取抑制剂（SRI）治疗反应有关。SLC1A1中的一种多态性（rs3056）与OCD患者脑容量改变有关。我们研究了这种多态性与OCD的关联及其与各种临床参数的关系，这些参数包括发病年龄、疾病严重程度、自知力、OCD经因子分析的症状维度以及SRI治疗反应。从一家专门的OCD诊所招募了377名年龄在18至60岁之间的OCD患者（符合《精神疾病诊断与统计手册第四版》[DSM-IV]标准）。为了研究与SRI治疗反应的关联，我们分析了对任何一种SRI有完全反应的患者（耶鲁布朗强迫症量表[YBOCS]评分降低≥35%且临床总体印象改善量表[CGI-I]评分为1或2；n = 187）以及对至少两种SRI进行了为期12周的充分试验但无反应的患者（YBOCS评分降低<25%且CGI-I评分>4；n = 91）。招募了健康对照者（n = 333），并使用简易国际神经精神访谈升级版（MINI-Plus）进行评估。所有受试者均来自印度南部，对其进行了SLC1A1多态性（rs3056）基因分型。基因型频率未显著偏离哈迪-温伯格平衡。病例对照关联分析显示，“GG”基因型在OCD病例中比在对照者中显著更常见（p = .04）。未发现与发病年龄、症状严重程度、自知力及症状维度有关联。未发现基因型/等位基因频率与治疗反应之间存在显著关联。总之，虽然SLC1A1 rs3056多态性与OCD之间存在显著关联，但与其他临床参数或治疗反应无显著关联。（《心理学文摘数据库记录》（c）2020美国心理学会，保留所有权利）
